Zionexa Comparisons
Developer of molecular imaging technology designed to diagnose metastatic breast cancer. The company's technology provid
Zionexa Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Where is Zionexa located?
Zionexa, a privately owned company, formed in 2018 and headquartered in Aubière, France, employs 24 people in France and the U.S., all of whom will transfer to GE Healthcare. Additionally, GE Healthcare will hire approximately 70 new dedicated employees within the company's U.S. Pharmaceutical Diagnostics team, headquartered in Marlborough, ...
What is Zionexa biomarker?
About Zionexa: Zionexa is an international and innovative company developing and commercializing in-vivo biomarkers for gu iding targeted therapies in oncology, to improve patients' pathway and provide them a better quality of life. For more information, please visit www.zionexa.com.
What is the FDA approved F-18?
Cerianna (fluoroestradiol F-18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer. For more information about Cerianna, please visit www.cerianna.com (accessible only for US HCPs) and find full Prescribing Information here .
Who owns Zionexa?
Zionexa, owned by Denos, has taken over the development of the most innovative molecules coming from Cyclopharma’s pipeline. The objective is to drive the development, commercialization, and access to American and international markets, beginning with Estrotep. EstroTep is a new biomarker, (currently approved for use in France) which can be used as an additional tool in patient care for metastatic breast cancer.
What is Zionexa CDX?
Paris (France), May 16th, 2018 – Zionexa, a new radiopharmaceutical company, has been created to develop and commercialize innovative molecular imaging diagnostic companions ( CDx) for targeted therapies in oncology that can improve patients’ pathway within the framework of new personalized diagnostic approaches.
Who is Zionexa acquired by?
Marlborough, MA, U.S. – 6 May 2021 – GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, ...
Where is Zionexa located?
Zionexa, a privately owned company, formed in 2018 and headquartered in Aubière, France, employs 24 people in France and the U.S., all of whom will transfer to GE Healthcare. Additionally, GE Healthcare will hire approximately 70 new dedicated employees within the company’s U.S. Pharmaceutical Diagnostics team, headquartered in Marlborough, ...
What is Zionexa biomarker?
Zionexa is an international and innovative company developing and commercializing in-vivo biomarkers for guiding targeted therapies in oncology, to improve patients’ pathway and provide them a better quality of life.
